Royal Bank of Canada
XERS icon

Royal Bank of Canada’s Xeris Biopharma Holdings XERS Stock Holding History

Royal Bank of Canada’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$253K Buy
43,610
+4,974
+13% +$33K ﹤0.01% 4562
2025
Q4 		$304K Buy
38,636
+2,351
+6% +$18.5K ﹤0.01% 4509
2025
Q3 		$295K Sell
36,285
-8,068
-18% -$53.6K ﹤0.01% 4837
2025
Q2 		$206K Sell
44,353
-168,731
-79% -$773K ﹤0.01% 5129
2025
Q1 		$1.17M Buy
213,084
+198,984
+1,411% +$803K ﹤0.01% 3348
2024
Q4 		$48K Sell
14,100
-16,160
-53% -$52K ﹤0.01% 5725
2024
Q3 		$86K Buy
30,260
+2,913
+11% +$7.48K ﹤0.01% 5445
2024
Q2 		$61K Buy
27,347
+8,813
+48% +$17.8K ﹤0.01% 5556
2024
Q1 		$42K Sell
18,534
-36,770
-66% -$95.1K ﹤0.01% 5622
2023
Q4 		$131K Buy
55,304
+32,507
+143% +$60K ﹤0.01% 5443
2023
Q3 		$43K Buy
22,797
+8,015
+54% +$18.4K ﹤0.01% 5862
2023
Q2 		$39K Buy
14,782
+4,355
+42% +$11.1K ﹤0.01% 5903
2023
Q1 		$17K Sell
10,427
-7,830
-43% -$9.8K ﹤0.01% 6095
2022
Q4 		$24K Buy
18,257
+13,045
+250% +$18.4K ﹤0.01% 6239
2022
Q3 		$9K Sell
5,212
-9,133
-64% -$15.1K ﹤0.01% 6490
2022
Q2 		$22K Sell
14,345
-29,060
-67% -$61.3K ﹤0.01% 6075
2022
Q1 		$111K Buy
43,405
+23,305
+116% +$56.9K ﹤0.01% 5576
2021
Q4 		$59K Sell
20,100
-2,400
-11% -$5.18K ﹤0.01% 6282
2021
Q3 		$55K Sell
22,500
-264,303
-92% -$767K ﹤0.01% 6107
2021
Q2 		$1.17M Buy
286,803
+8,228
+3% +$31.4K ﹤0.01% 3517
2021
Q1 		$1.26M Buy
278,575
+67,920
+32% +$366K ﹤0.01% 3381
2020
Q4 		$1.04M Buy
210,655
+42,704
+25% +$214K ﹤0.01% 3457
2020
Q3 		$996K Buy
167,951
+26,037
+18% +$104K ﹤0.01% 3265
2020
Q2 		$377K Sell
141,914
-796
-0.6% -$2.77K ﹤0.01% 3997
2020
Q1 		$278K Buy
142,710
+98,807
+225% +$425K ﹤0.01% 4094
2019
Q4 		$309K Buy
43,903
+2,327
+6% +$19.2K ﹤0.01% 4317
2019
Q3 		$409K Buy
41,576
+21,603
+108% +$243K ﹤0.01% 3971
2019
Q2 		$228K Sell
19,973
-1,835
-8% -$19.3K ﹤0.01% 4399
2019
Q1 		$219K Buy
21,808
+14,340
+192% +$184K ﹤0.01% 4305
2018
Q4 		$127K Buy
7,468
+1,117
+18% +$22.4K ﹤0.01% 4606
2018
Q3 		$112K Buy
+6,351
New +$138K ﹤0.01% 4799

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada's XERS Position: Q1 2026 in Review

Royal Bank of Canada increased its Xeris Biopharma Holdings (XERS) stake by 13% in Q1 2026, buying an estimated $33K and bringing the position to 43,610 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #4562.

Royal Bank of Canada first reported a position in XERS in Q3 2018 and has held it in 31 quarters since. The position peaked at $1.26M in Q1 2021. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Royal Bank of Canada held 43,610 shares of Xeris Biopharma Holdings worth $253K as of Q1 2026.
  • Royal Bank of Canada bought 4,974 Xeris Biopharma Holdings shares in Q1 2026, an estimated $33K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4562 holding.
  • Royal Bank of Canada first reported a position in Xeris Biopharma Holdings in Q3 2018 and has held it in 31 quarters since.
  • Royal Bank of Canada's Xeris Biopharma Holdings position peaked at $1.26M in Q1 2021.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.